Heart/Cardiovascular

The Arizona Respiratory Neurophysiology Laboratory (ARNL) is investigating the effects of a novel exercise training known as Respiratory Muscle Training (RMT) on sleep and cardiovascular function in adults 50 years of age and older who suffer from obstructive sleep apnea (OSA) and elevated blood pressure.

Primary disease category: 
Secondary disease category(ies): 

The REDUCE LAP-HF II study is
evaluating the IASD® System II,
a non-surgical, medical device
designed to improve quality
of life by potentially reducing
breathlessness and fatigue.

Primary disease category: 

The purpose of this study is to determine if treatment with omecamtiv mecarbil/AMG 423 when added to standard of care is well tolerated and superior to placebo in reducing the risk of cardiovascular death or heart failure events in subjects with chronic HFrEF.

Primary disease category: 

Peripheral arterial disease (PAD) affects millions of patients in the United States and has been a key focus of research for our group at the Southern Arizona Limb Salvage Alliance (SALSA). PAD is caused by genetic factors as well as hyperlipidemia, smoking, hypertension and diabetes. Care for patients with PAD focuses on medical optimization, mechanical optimization, wound care and surgical revascularization, without which patients have a large degree of impairment resulting from chronic wounds and amputations.

Primary disease category: 

Torsades de pointes (TdP) is a rare life threatening heart arrhythmia. It occurs in individuals with genetic mutations in genes that control the expression of ion channel proteins in the heart and is a frequent cause of sudden death in these individuals. TdP also occurs as a complication of drugs that prolong a cardiac timing interval by blockade of potassium channels. This list of drugs includes the antibiotics erythromycin, azithromycin, clarithromycin, levofloxacin and ciprofloxacin.

Primary disease category: 

The PEARL Study is evaluating the safety and effectiveness of coronary angiography performed within 90 minutes of hospital arrival in a population of post-cardiac arrest patients without ST Segment elevation on their electrocardiograms (ECGs).

Primary disease category: 

The purpose of this study is to assess the effectiveness and safety of rivaroxaban compared with placebo (inactive medication), in reducing the risk of death, heart attack or stroke in participants with heart failure and significant coronary artery disease following an episode of decompensated heart failure.

Primary disease category: 

The Prehospital Resuscitation On Helicopter Study (PROHS) is a pragmatic, multicenter, prospective observational study of air ambulance-based prehospital resuscitation regimens currently utilized at the participating sites. Patients will be enrolled at participating sites that currently have blood products available on air ambulances and other sites that do not. This study will not change the current prehospital standard of care for resuscitation. The primary outcome will be 30 day in-hospital mortality and the primary unit of analysis will be the patient.

Primary disease category: 
Subscribe to RSS - Heart/Cardiovascular